FVC2224. Opening Remarks and Awards Presentation | KEYNOTE: Bad Blood: Secrets and Lies in a Silicon Valley Startup
Drawing on his bestselling book and including updates from the Elizabeth Holmes and Sunny Balwani trials, Carreyrou will discuss the ethical lapses, the credulous media coverage, and the lax oversight that allowed Theranos to achieve a “unicorn” valuation of $9 billion, as well as the lessons CPAs and other professionals can learn from its fall.
- Recall the chronology of how the Theranos fraud unfolded, with updates from the recent trials
- Identify how Carreyrou’s investigative reporter’s toolkit helped him uncover malfeasance that had been missed by so many others